Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. - Wikidata - wikimedia - TriplyDB

Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

http://www.wikidata.org/entity/Q37403232

about

Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

http://www.wikidata.org/entity/Q37403232

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Radiosensitizers in pancreatic ...... h molecularly targeted agents.

@en

Radiosensitizers in pancreatic ...... h molecularly targeted agents.

@nl

type

label

Radiosensitizers in pancreatic ...... h molecularly targeted agents.

@en

Radiosensitizers in pancreatic ...... h molecularly targeted agents.

@nl

prefLabel

Radiosensitizers in pancreatic ...... h molecularly targeted agents.

@en

Radiosensitizers in pancreatic ...... h molecularly targeted agents.

@nl

P1433

Q37403232-9FBBD998-9546-4CED-8DE8-5E04AB0022ED

P1476

Q37403232-7ADEBB25-2EEC-4635-9186-937CED48966F

P2093

Q37403232-2A0BA47A-13B6-41EF-822F-B4E6AC445668

Q37403232-66A1F19A-C78A-45CE-B40E-A02600AF9B7A

Q37403232-7CB3CE64-7AB3-4BF6-9D76-57FBB7F3CE1E

Q37403232-855BBEA4-AAA1-4F49-9F9F-9CB3C756E165

Q37403232-9A1479ED-B0E6-43A2-89A5-1137175EF88A

Q37403232-ED59B195-F449-4647-AD91-F1E6F7019DF9

P2860

Q37403232-0617E287-B42E-4CEB-9243-234F078854EB

Q37403232-07F3002D-EE5C-4A69-8551-394D9047BF52

Q37403232-0C429344-C53B-460F-833A-ACEEEAA10F20

Q37403232-15C9611B-F50A-454D-BF7B-BEE027766061

Q37403232-17C34F02-4037-473F-AEC8-6D50BDC606FA

Q37403232-18F0F20E-ED5A-4E7F-8190-666BB0FAD701

Q37403232-194FCED7-F40A-4963-A65F-031C040447A0

Q37403232-1D8922DA-C77F-4A5E-8BE6-F509F413A3BF

Q37403232-1E20C2DD-5C7F-44E9-9B8E-78E728BA93E8

Q37403232-215B381C-89FF-42D0-9EF7-A555F13B26C7

P304

Q37403232-499BD542-81AB-449F-AC49-28993EED612A

P31

Q37403232-5EF3CD55-57F7-4D22-82BD-BBD5452A1575

P356

Q37403232-2C568577-7F20-48D5-B378-CBDE54D6B746

P433

Q37403232-D4C7AA63-41A3-4642-B21A-379B928CB3E0

P478

Q37403232-7E467283-6EB5-4E98-B237-787DAD8898C9

P50

Q37403232-FD824759-2336-4B37-93D8-AA9E4840262F

P577

Q37403232-85B65972-03FD-4628-A5AD-66EF8A52CFE6

P698

Q37403232-EE16411D-F743-4668-88F8-67726190B3CB

P932

Q37403232-F3AEC895-4DA5-4B0D-8663-02DCC64A7990

P356

J.CURRPROBLCANCER.2013.10.008

P1433

Current Problems in Cancer

P1476

Radiosensitizers in pancreatic ...... th molecularly targeted agents

@en

P2093

Aaron T Wild

http://www.w3.org/2001/XMLSchema#string

Amanda J Walker

http://www.w3.org/2001/XMLSchema#string

Amol K Narang

http://www.w3.org/2001/XMLSchema#string

Joseph M Herman

http://www.w3.org/2001/XMLSchema#string

Katriana M Nugent

http://www.w3.org/2001/XMLSchema#string

Sara R Alcorn

http://www.w3.org/2001/XMLSchema#string

P2860

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Hallmarks of Cancer: The Next Generation

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Cancer statistics, 2012

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

P304

301-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CURRPROBLCANCER.2013.10.008

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24331186

http://www.w3.org/2001/XMLSchema#string

P932

3868005

http://www.w3.org/2001/XMLSchema#string